What the company does:
Specifically, its technology detects evidence of the body's natural response to cancer, enabling detection four years or more before standard clinical diagnosis.
Founded in 2002, it launched its platform technology in 2009, followed by its first commercial tests - EarlyCDT-Lung and EarlyCDT-Liver.
To date, over 155,000 Oncimmune tests have been performed worldwide.
EarlyCDT-Lung was used in the largest-ever trial for the early detection of lung cancer using biomarkers - the National Health Service's Early Cancer Detection Test-Lung Cancer Scotland (ECLS) study of 12,210 high-risk smokers in Scotland.
Oncimmune also develops precision medicine and patient tools that allow doctors to place people being treated for cancer and autoimmune diseases into certain patient sub-groups, a process called stratification.
Scottish NHS study success:
A total of 12,210 Scots were monitored for two years as part of the ECLS initiative in what is believed to be the largest randomised controlled assessment of its kind.
Sponsored by the University of Dundee and NHS Tayside and co-funded by the Chief Scientist Office, the study, to use the scientific parlance, hit its primary end-point.
Specifically, monitoring recruits reduced the incidence of people with late-stage lung cancer, or “unclassified presentation at diagnosis”, compared to standard clinical practice.
- In early November, Oncimmune clinched a commercialisation deal with US diagnostics firm Biodesix for its EarlyCDT Lung cancer test.
- The deal, originally announced in June, will be worth up to US$28mln over the next five years, with the agreement open for renewal for another five year period up to 2029 and thereafter
- In September, the company presented positive trial data from its EarlyCDT Lung test were presented at the World Conference for Lung Cancer in Barcelona
What the broker says
Oncimmune has “substantially reduced” the commercial launch risk for its EarlyCDT lung cancer test through a series of supply and licence deals, according to analysts at finnCap.
In a note initiating the biotech firm with a price target of 150p, the broker said the company’s business model reduced execution risk through deals in the US and China, distribution agreements in 23 additional markets and “a diversifying pipeline of revenues”.
As a result, the broker expected “early evidence of the revenue ramp” in the current year, predicting £400,000 in revenues for the first half of the 2020 financial year and £800,000 for the second half.
FinnCap also expects Oncimmune to be cash flow positive by 2024, while its current cash balance, which provides funds until 2022, would provide “the time to deliver further meaningful valuation points”.